A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscleinvasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701) Meeting Abstract

  

Authors:	Iyer, G.; Ballman, K. V.; Atherton, P. J.; Murray, K.; Kwok, Y.; Steen, P. D.; Baghaie, S.; Rosenberg, J. E.; Morris, M. J.
Abstract Title:	A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscleinvasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)
Meeting Title:	2022 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	16 Suppl.
Meeting Dates:	2022 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-06-01
Language:	English
ACCESSION:	WOS:000863680304967
PROVIDER:	wos
DOI:	10.1200/JCO.2022.40.16_suppl.TPS4615
Notes:	Meeting Abstract: TPS4615 -- Meeting also held virtually -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201414